Cellosaurus logo
expasy logo

Cellosaurus SJNB-6 (CVCL_8823)

[Text version]
Cell line name SJNB-6
Synonyms SJ-NB-6; SJ-NB6; SJNB6; NB6; NB6-DH; N2307L
Accession CVCL_8823
Secondary accession CVCL_1447
Resource Identification Initiative To cite this cell line use: SJNB-6 (RRID:CVCL_8823)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (Cosmic-CLP; DepMap).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.42
Native American0
East Asian, North0.32
East Asian, South0.64
South Asian4.28
European, North52.61
European, South41.73
Disease Neuroblastoma (NCIt: C3270)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP

Markers:
AmelogeninX,Y
CSF1PO12
D5S81813
D7S8208,11
D13S3178,13
D16S5399,12
TH018,9
TPOX8
vWA17,18

Run an STR similarity search on this cell line
Publications

PubMed=8516298; DOI=10.1073/pnas.90.12.5539
Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., Lowy D.R.
Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras.
Proc. Natl. Acad. Sci. U.S.A. 90:5539-5543(1993)

PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=10935473; DOI=10.1038/sj.neo.7900010
Kong X.-T., Valentine V.A., Rowe S.T., Valentine M.B., Ragsdale S.T., Jones B.G., Wilkinson D.A., Brodeur G.M., Cohn S.L., Look A.T.
Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines.
Neoplasia 1:80-89(1999)

PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)

PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)

PubMed=18923524; DOI=10.1038/nature07399
Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S.
Oncogenic mutations of ALK kinase in neuroblastoma.
Nature 455:971-974(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20655465; DOI=10.1016/j.cell.2010.06.004
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resources CLO; CLO_0037089
cancercelllines; CVCL_8823
Cell_Model_Passport; SIDM00253
Cosmic-CLP; 949173
DepMap; ACH-002284
LINCS_LDP; LCL-1996
Anatomy/cell type resources BTO; BTO:0006054
CRISP screens repositories BioGRID_ORCS_Cell_line; 950
Chemistry resources ChEMBL-Cells; CHEMBL3308157
ChEMBL-Targets; CHEMBL2366318
GDSC; 949173
PharmacoDB; NB6_992_2019
PubChem_Cell_line; CVCL_8823
Encyclopedic resources Wikidata; Q54953578
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM314024
GEO; GSM333811
GEO; GSM692877
GEO; GSM1670153
Polymorphism and mutation databases Cosmic; 688082
Cosmic; 949173
Cosmic; 1037336
Cosmic; 1099133
Cosmic; 1109117
Cosmic; 1153797
Cosmic; 1518074
Cosmic; 1526642
IARC_TP53; 27179
Progenetix; CVCL_8823
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation06-Jun-2012
Last entry update30-Jan-2024
Version number35